Contribution of the AIM2 inflammasome to chronic inflammation in patients with Myelofibrosis

GOETTE NP; CASTRO RIOS M; CORTES V; BENDEK G; VARELA A; LARRIPA IB; HELLER PG; DE LUCA, GERALDINE; CAMACHO MF; MOIRAGHI B; VERRI V; VICENTE A; GUTIERREZ M; GLEMBOTSKY AC; LEV PR; SACKMANN F; CAULA V; CARRICONDO E; VALLEJOS V; MARTA RF

Mar del Plata

Congreso; Reunión anual de Biociencias 2022 y LXVII Reunión anual de Sociedad Argentina de Investigación Clínica; 2022

Sociedad Argentina de Investigación Clínica

Myelofibrosis (MF) is a myeloproliferative neoplasm associated with poor outcome. It is caused by driver (JAK2/CALR/MPL) and high-risk mutations (HRM) associated to a chronic inflammatory process that accentuates the disease. In a previous work we described high levels of cell-free DNA (cfDNA) in MF patients that increase as disease progresses. cfDNA has pro-inflammatory effects being one of its targets the AIM2 inflammasome, responsible for maturation and release of IL-1β and IL-18 and involved in pyroptotic cell death.The aim of this work was to assess the activation of the inflammasome in MF patients and the role of AIM2 in monocytes. IL-18, an inflammasome product, was elevated in plasma from MF patients (n=66) vs. controls (P